+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2025-2030- Product Image
GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2025-2030- Product Image
Sale

GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6120806
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

GalNAc-oligonucleotide conjugates are rapidly redefining targeted drug delivery in the biopharmaceutical sector, offering a scalable pathway to precise liver-specific therapeutics. Senior leaders seeking to navigate the evolving competitive and regulatory environment need a comprehensive analysis that clarifies segmentation patterns, trade impacts, and strategic growth opportunities for informed investment and portfolio management decisions.

Market Snapshot: GalNAc-Oligonucleotide Conjugate Market Overview

The GalNAc-oligonucleotide conjugate market is witnessing sustained growth, fueled by increasing adoption in precision medicine and expanding R&D pipelines across diverse therapeutic areas. Notable advancements in conjugation chemistry and delivery strategies have enhanced both product reliability and commercial attractiveness. Market performance is supported by robust partnerships, strategic manufacturing investments, and a responsive regulatory climate, collectively accelerating clinical translation and market entry.

Scope & Segmentation: Strategic Market Segments and Geographic Coverage

This report provides a structured analysis of the GalNAc-oligonucleotide sector, categorizing key market components vital for decision-makers:

  • Product Type: Antisense oligonucleotides, aptamers, miRNA modulators, and siRNA constructs.
  • Therapeutic Application: Infectious diseases, metabolic disorders, oncology, and rare diseases.
  • Route of Administration: Intravenous and subcutaneous formulations, with granularity by clinical and preclinical stage.
  • End User: Biotechnology companies, contract research organizations, large pharmaceutical firms, and small pharmaceutical companies focused on niche specialties.
  • Distribution Channel: Direct sales and distributor-based engagement models.
  • Regional Coverage: Americas (including the US, Canada, and several Latin American countries), Europe, Middle East & Africa (covering all major sub-regions), and Asia-Pacific (including China, India, Japan, and others).
  • Industry Leaders: Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Eurofins Scientific SE, Maravai LifeSciences Holdings, Inc., Azenta, Inc., GenScript Biotech Corporation, WuXi AppTec Co., Ltd., BGI Genomics Co., Ltd., and Takara Bio Inc.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Recent advancements in GalNAc conjugation chemistry have enabled next-generation oligonucleotide therapeutics with enhanced liver targeting and reduced risk of off-target effects.
  • Refined multivalent N-acetylgalactosamine ligands and backbone modifications are improving binding affinity, intracellular delivery, and stability, widening therapeutic potential across clinical areas.
  • Collaborative models between large pharma and specialized biotech firms have accelerated R&D timelines, enabled knowledge exchange, and improved technology transfer.
  • Portfolio strategies increasingly prioritize platforms integrating GalNAc technology with complementary delivery systems, unlocking applications beyond hepatic indications.
  • Regional expansion is bolstered by diverse regulatory frameworks and investments in localized manufacturing, strengthening supply security and access to emerging markets.

Tariff Impact: Navigating New Cost Dynamics in the GalNAc-Oligonucleotide Market

Upcoming United States tariff policies are set to influence raw material sourcing, contract manufacturing, and overall cost structures in 2025 and beyond. Increased tariffs on essential chemical reagents could drive manufacturers to diversify supplier bases and explore near-shoring or regional production. Companies with vertically integrated supply chains are expected to better withstand pricing volatility, while collaborative manufacturing agreements may offer pathways to circumvent tariff barriers and maintain R&D momentum.

Methodology & Data Sources

Our analysis integrates extensive secondary research from peer-reviewed literature, intellectual property landscapes, and regulatory submissions. This is complemented by targeted primary interviews with discovery scientists, clinical development leaders, and manufacturing experts. Findings are validated via advisory panel reviews and scenario modeling to ensure high-integrity insights for executive review.

Why This Report Matters: Strategic Value for Industry Leaders

  • Offers actionable segmentation and regional analyses to guide portfolio prioritization and mitigate operational risks in a dynamic regulatory context.
  • Delivers insight into collaboration strategies, supply chain architectures, and technology integration, supporting robust decision-making in product development and commercialization.

Conclusion: Future-Ready Strategies for GalNAc-Oligonucleotide Investment

Industry leaders who embrace supply chain agility, invest in collaborative R&D, and proactively assess emerging delivery approaches will be positioned to capitalize on growth opportunities and drive value creation in the GalNAc-oligonucleotide market.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Optimization of multivalent GalNAc ligand architectures to improve oligonucleotide endosomal escape and target specificity
5.2. Advancements in novel conjugation chemistries to increase stability and reduce immunogenicity of GalNAc oligonucleotides
5.3. Expansion of GalNAc-siRNA pipeline into chronic liver diseases beyond hypercholesterolemia and hereditary transthyretin amyloidosis
5.4. Real-world evidence on the long-term efficacy and cost-effectiveness of Inclisiran in cardiovascular risk management
5.5. Development of next-generation GalNAc conjugates with controlled release profiles for personalized RNA therapeutics
5.6. Regulatory and reimbursement challenges shaping market access for GalNAc oligonucleotide therapies in emerging markets
5.7. Innovations in oral delivery formulations for GalNAc conjugated oligonucleotides to enable noninvasive dosing strategies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. GalNAc-Oligonucleotide Conjugates Market, by Product Type
8.1. Introduction
8.2. Antisense Oligonucleotides
8.3. Aptamers
8.4. MiRNA
8.5. SiRNA
9. GalNAc-Oligonucleotide Conjugates Market, by Therapeutic Application
9.1. Introduction
9.2. Infectious Diseases
9.3. Metabolic Disorders
9.4. Oncology
9.5. Rare Diseases
10. GalNAc-Oligonucleotide Conjugates Market, by Route of Administration
10.1. Introduction
10.2. Intravenous
10.3. Subcutaneous
10.3.1. Clinical Stage
10.3.2. Preclinical Stage
11. GalNAc-Oligonucleotide Conjugates Market, by End User
11.1. Introduction
11.2. Biotechnology Companies
11.3. Contract Research Organizations
11.4. Pharmaceutical Companies
11.4.1. Large Pharma
11.4.2. Small Pharma
12. GalNAc-Oligonucleotide Conjugates Market, by Distribution Channel
12.1. Introduction
12.2. Direct Sales
12.3. Distributors
13. Americas GalNAc-Oligonucleotide Conjugates Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa GalNAc-Oligonucleotide Conjugates Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific GalNAc-Oligonucleotide Conjugates Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. Merck KGaA
16.3.3. Danaher Corporation
16.3.4. Eurofins Scientific SE
16.3.5. Maravai LifeSciences Holdings, Inc.
16.3.6. Azenta, Inc.
16.3.7. GenScript Biotech Corporation
16.3.8. WuXi AppTec Co., Ltd.
16.3.9. BGI Genomics Co., Ltd.
16.3.10. Takara Bio Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET: RESEARCHAI
FIGURE 26. GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET: RESEARCHSTATISTICS
FIGURE 27. GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET: RESEARCHCONTACTS
FIGURE 28. GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY MIRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY MIRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRECLINICAL STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRECLINICAL STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SMALL PHARMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SMALL PHARMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 93. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 96. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 97. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 100. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 101. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 104. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 105. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. CANADA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 110. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 111. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 114. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 115. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 118. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 119. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. MEXICO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 180. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 181. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 182. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 183. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 186. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 187. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 190. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 191. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. GERMANY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 196. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 197. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 200. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 201. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 204. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 205. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. FRANCE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 228. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 229. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 232. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 233. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. ITALY GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 236. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 237. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 238. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 239. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 242. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 243. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 246. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 247. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. SPAIN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this GalNAc-Oligonucleotide Conjugates market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Eurofins Scientific SE
  • Maravai LifeSciences Holdings, Inc.
  • Azenta, Inc.
  • GenScript Biotech Corporation
  • WuXi AppTec Co., Ltd.
  • BGI Genomics Co., Ltd.
  • Takara Bio Inc.

Related Reports

GalNac Conjugates Market - Global Forecast 2025-2030 - Product Image

GalNac Conjugates Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
GalNAc-ASO Conjugates Market - Global Forecast 2025-2030 - Product Image

GalNAc-ASO Conjugates Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
RNA Interference- Pipeline Insight, 2025 - Product Image

RNA Interference- Pipeline Insight, 2025

  • Drug Pipelines
  • 204 Pages
  • Global
From
Alpha-1 Antitrypsin Deficiency- Pipeline Insight, 2025 - Product Image

Alpha-1 Antitrypsin Deficiency- Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
RNA-based Therapeutics - Global Strategic Business Report - Product Image

RNA-based Therapeutics - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.